STRATEC SE : Preliminary results and reduced sales guidance, bottom line positive
>Weak bottom line, but margin development positive - Stratec reported Q3 2022 revenues of € 70.5m (+1.3% y-o-y), which were 14% below our forecast of € 82.0m. We calculate a sales decline in constant currencies of around 5%, which came on the back of a comparable high base in 2021 due to the coronavirus-pandemic and ongoing high supply constraints. Contrary to previous expectations, delivery backlogs rose further throughout the third quarter on the back of supply cons...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.